BridgeBio Oncology Therapeutics, Inc. (BBOT) fair value analysis
Nasdaq · Updated 2026-10-19
BBOT price how computed
Valuation status
No fair-value estimate yetBBOT has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for BBOT yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $2.82
- Sector
- Healthcare
- 12-month range
- $2.82–$13.73
- Market cap
- $226M
- From 52-week high
- -79.5%
- Shares outstanding
- 80.2M
- Rank in Healthcare by quality score
- #223 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
BridgeBio Oncology Therapeutics, Inc. is a biotechnology company that develops and commercializes medicines for patients with cancer and other serious diseases. The company operates primarily in the United States and conducts its research and development activities across multiple locations to advance its therapeutic pipeline.
BBOT currently ranks #223 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $226M
- P/E (trailing)
- n/m
- EPS (TTM)
- $-528.34
- Debt / equity
- 0.01
- Shares outstanding
- 80.2M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 12 · oversold
- 50-day average
- $6.30
- 200-day average
- $8.61
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-11
- Last 4 quarters vs consensus
- 1 beat, 3 missed
- Quarter by quarter
- 2026-06 ▼ miss (-29.1%)
2026-03 ▼ miss (-102777.3%)
2025-12 ▲ beat (+25.8%)
2025-09 ▼ miss (-202.9%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 11 buy · 0 hold · 0 sell (11 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $24.6
- Target vs last price
- +772.3%
What our data shows for BBOT
- Shares are trading in the lower third of their 12-month price range of $2.82–$13.73.
- The 14-day relative strength index sits at an oversold 12.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- BBOT's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the BBOT conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is BBOT stock undervalued?
TickrTrends has no fair-value estimate for BBOT yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is BBOT's TickrTrends verdict?
BBOT is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does BBOT compare to other Healthcare stocks?
BBOT ranks #223 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is BBOT overbought or oversold?
BBOT's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does BBOT report earnings next?
BBOT's next earnings report is scheduled for 2026-11-11, per the published earnings calendar.
Does BBOT usually beat earnings estimates?
Over its last 4 reported quarters BBOT beat the consensus estimate 1 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about BBOT?
Of 11 analysts covering BBOT, 11 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $24.6 (+772.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.